Pharmacological Characterization of RS-1259, an Orally Active Dual Inhibitor of Acetylcholinesterase and Serotonin Transporter, in Rodents: Possible Treatment of Alzheimer’s Disease
Open Access
- 1 January 2003
- journal article
- research article
- Published by Japanese Pharmacological Society in Journal of Pharmacological Sciences
- Vol. 93 (1), 95-105
- https://doi.org/10.1254/jphs.93.95
Abstract
A dual inhibitor of acetylcholinesterase (AChE) and serotonin transporter (SERT), RS-1259 (4-[1S)-methylamino-3-(4-nitrophenoxy)]propylphenyl N,N-dimethylcarbamate (fumaric acid)1/2salt), was newly synthesized. RS-1259 simultaneously inhibited AChE and SERT in the brain following an oral administration in mice and rats. Actual simultaneous elevation of extracellular levels of 5-HT and ACh in the rat hippocampus was confirmed by microdialysis. The compound was as effective as SERT inhibitors such as fluoxetine and fluvoxamine in a 5-hydroxytryptophan-enhancing test in mice. Spatial memory deficits in the two-platform task of a water maze in aged rats were ameliorated by RS-1259 as well as donepezil. Both RS-1259 and donepezil increased the awake episodes in the daytime electroencephalogram of rats. Although RS-1259 was weaker than donepezil in enhancing central cholinergic transmission, as observed by ACh elevation in the hippocampus and memory enhancement in aged rats, the efficacy of RS-1259 on the consciousness level, which reflects the whole activity in the brain, was almost the same as that of donepezil. These results suggest that both cholinergic and serotonergic systems are involved in maintaining brain arousal and that a dual inhibitor of AChE and SERT may be useful for the treatment of cognitive disorders associated with reduced brain activity such as in Alzheimer’s disease.Keywords
This publication has 29 references indexed in Scilit:
- Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trialBMJ, 2000
- A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon®)European Journal of Neurology, 1999
- A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's diseaseNeurology, 1998
- Cholinesterase Inhibitors in the Treatment of Alzheimer??s DiseaseDrug Safety, 1998
- Monoamine neurons in aging and Alzheimer's diseaseJournal of Neural Transmission, 1993
- The role of interactions between the cholinergic system and other neuromodulatory systems in learing and memorySynapse, 1991
- Age-related changes in multiple neurotransmitter systems in the monkey brainNeurobiology of Aging, 1989
- Oral Tetrahydroaminoacridine in Long-Term Treatment of Senile Dementia, Alzheimer TypeNew England Journal of Medicine, 1986
- NON-CHOLINERGIC NEUROTRANSMITTER ABNORMALITIES IN ALZHEIMER'S DISEASEBritish Medical Bulletin, 1986
- SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASEThe Lancet, 1976